Treatment benefits patients with thalassaemia and HCV

Many individuals with the blood disorder thalassaemia also carry the hepatitis C virus (HCV) due to contaminated transfusions before 1990. Due to the co-existence of iron overload (from repeated blood transfusions), these patients are at increased risk of developing liver cancer. A new study indicates that treatment with a combination of sofosbuvir and ledipasvir as a once a day single pill leads to a sustained virological response in 98% of patients with thalassaemia and HCV.

"The findings are significant because, unlike other antiviral drugs, this simple treatment is expected not to be limited by drug-to-drug interactions with other medications usually taken by thalassaemia patients," said Dr. Alessandra Mangia, lead author of the Alimentary Pharmacology & Therapeutics study.

###

Media Contact

Penny Smith
[email protected]

http://newsroom.wiley.com/

http://dx.doi.org/10.1111/apt.14197

Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: